My thoughts exactly. Literally just posted something similar in the other thread. The flip side is Patrersons push the price down so they get more cheap shares from underwriting.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%